for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dova Pharmaceuticals Inc

DOVA.OQ

Latest Trade

28.25USD

Change

0.11(+0.39%)

Volume

30,447

Today's Range

28.11

 - 

28.32

52 Week Range

5.62

 - 

28.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
28.14
Open
28.13
Volume
30,447
3M AVG Volume
11.03
Today's High
28.32
Today's Low
28.11
52 Week High
28.49
52 Week Low
5.62
Shares Out (MIL)
28.80
Market Cap (MIL)
810.48
Forward P/E
-11.46
Dividend (Yield %)
--

Next Event

Dova Pharmaceuticals Inc at Stifel Healthcare Conference

Latest Developments

More

Sobi To Acquire Dova Pharmaceuticals

Dova Pharmaceuticals To Be Acquired By Swedish Orphan Biovitrum AB

Dova Pharmaceuticals Reports Second Quarter 2019 Operating And Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dova Pharmaceuticals Inc

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Industry

Biotechnology & Drugs

Contact Info

240 Leigh Farm Rd

+1.919.8064487

http://dova.com/

Executive Leadership

Paul B. Manning

Chairman of the Board

David S. Zaccardelli

President, Chief Executive Officer

Mark W. Hahn

Chief Financial Officer

Kevin Laliberte

Senior Vice President - Product Development

Lee F Allen

Chief Medical Officer

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-1.400

2018

-2.600

2019(E)

-2.455
Price To Earnings (TTM)
--
Price To Sales (TTM)
60.99
Price To Book (MRQ)
15.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.74
LT Debt To Equity (MRQ)
38.43
Return on Investment (TTM)
-71.38
Return on Equity (TTM)
-63.30

Latest News

Latest News

Sobi to buy Dova Pharmaceuticals to broaden portfolio, boost U.S. presence

Rare diseases specialist Swedish Orphan Biovitrum (Sobi) <SOBIV.ST> said it had agreed to buy Dova Pharmaceuticals in a deal valuing the U.S. firm at up to $915 million.

BRIEF-Dova Pharmaceuticals Announces Proposed Offering Of Common Stock

* DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln Shares

* DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2FgTI9o) Further company coverage:

BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

* DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer

* DOVA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARK W. HAHN AS CHIEF FINANCIAL OFFICER

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA

* Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist

BRIEF-Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32

* Dova Pharmaceuticals reports second quarter 2017 operating and financial results

BRIEF-Perceptive Advisors reports 6.8 pct passive stake in Dova Pharma

* Perceptive Advisors Llc reports a 6.8 pct passive stake in Dova Pharmaceuticals Inc as of July 5 - SEC filing Source text: (http://bit.ly/2uQUtT6)

BRIEF-Dova Pharma sees IPO to be priced between $15 and $17/shr

* Dova Pharmaceuticals Inc sees IPO of upto 4.06 million shares of common stock to be priced between $15 and $17 per share - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up